This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (685) Digital Biomarkers and Digital Phenotyping (284)

Published on in Vol 12 (2023)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/42032, first published .
An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study

An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study

An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study

Authors of this article:

Shotaro Haji1 Author Orcid Image ;   Koji Fujita1 Author Orcid Image ;   Ryosuke Oki1 Author Orcid Image ;   Yusuke Osaki1 Author Orcid Image ;   Ryosuke Miyamoto1 Author Orcid Image ;   Hiroyuki Morino2 Author Orcid Image ;   Seiichi Nagano3, 4 Author Orcid Image ;   Naoki Atsuta5 Author Orcid Image ;   Yuki Kanazawa6 Author Orcid Image ;   Yuki Matsumoto7 Author Orcid Image ;   Atsuko Arisawa8 Author Orcid Image ;   Hisashi Kawai9 Author Orcid Image ;   Yasutaka Sato10 Author Orcid Image ;   Satoshi Sakaguchi10 Author Orcid Image ;   Kenta Yagi10 Author Orcid Image ;   Tatsuto Hamatani11 Author Orcid Image ;   Tatsuo Kagimura12 Author Orcid Image ;   Hiroaki Yanagawa10 Author Orcid Image ;   Hideki Mochizuki4 Author Orcid Image ;   Manabu Doyu5 Author Orcid Image ;   Gen Sobue13 Author Orcid Image ;   Masafumi Harada7 Author Orcid Image ;   Yuishin Izumi1 Author Orcid Image
Article Authors Cited by (6) Tweetations (2) Metrics

Journals

  1. Capriglia F, Burgess T, Bandmann O, Mortiboys H. Clinical Trial Highlights: Modulators of Mitochondrial Function. Journal of Parkinson’s Disease 2023;13(6):851 View
  2. Hamatani T, Atsuta N, Sano F, Nakamura R, Hayashi Y, Sobue G. ALSFRS-R decline rate prior to baseline is not useful for stratifying subsequent progression of functional decline. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2024;25(3-4):388 View
  3. Rodríguez‐Valdez G, Martínez‐Cerda M, Mejía‐Reyes J, Tapia‐Juárez M, Olmos‐Orizaba E, Cortés‐Rojo C, Cortés‐García C, Contreras‐Celedón C, Solorio‐Alvarado C, Chacón‐García L. A Metastable Semiquinone Molecular Switch Modulated by Ascorbate/O2: A Study from a System Far‐From‐Equilibrium to Biological Assays in Mitochondria. ChemBioChem 2024;25(18) View
  4. Filippi M, Ghirelli A, Spinelli E, Agosta F. A comprehensive update on neuroimaging endpoints in amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics 2025;25(4):397 View
  5. Tanveer S, Bajpai A, Rajput S, Saravanan P, Patel B. Targeting oxidative stress to combat neurodegenerative diseases, amyotrophic lateral sclerosis and Huntington’s, for better brain health and recovery. Current Opinion in Physiology 2025;46:100872 View

Books/Policy Documents

  1. Firdous S, Pal S, Mandal S, Sindhu R. Antioxidants. View